PTO/SB/05 (08-00)

Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control

Title

## UTILITY PATENT APPLICATION **TRANSMITTAL**

PH-7176 Attorney Docket No.

First Inventor or Application Identifier

Shuang Liu

STABLE RADIOPHARMACEUTICAL COMPOSITIONS AND METHODS FOR PREPARATION THEREOF

(Only for new nonprovisional applications under 37 C F R § 1 53(b))

Express Mail Label No EL387242730US

	APPLICA	NTS	Assistant Commissioner for Patents  ADDRESS TO Box Patent Application						
See MPEP chi	apter 600 concerning	ation contents.	Washington, DC 20231						
1. Fe (Si 2. Ap Se 3. Sp (pr - D - S - R - B	be Transmittal Form ubmit an original and opplicant claims smale a 37 CFR 1.27. Decification referred arrangement rescriptive title of the literature of the	7) processing) Pages 127]  D a computer	7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. Computer Readable Form (CRF) b. Specification Sequence Listing on: i. CD-ROM or CD-R (2 copies); or ii. paper c. Statements verifying identity of above copies  ACCOMPANYING APPLICATIONS PARTS  9. Assignment Papers (cover sheet & document(s))						
- Detailed Description - Claim(s) - Abstract of the Disclosure  - Drawing(s) (35 U.S.C.113)  - Detailed Description (when there is an assignee)  - Attorney  11.  - English Translation Document (if applicable)  12.  - Information Disclosure								Attorney ent (if applicable)  Copies of IDS Citations  PEP 503) ized) ocument(s)	
17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:  Continuation Divisional Continuation-in-part (CIP) of prior application No Group Art Unit For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying or divisional application and is hereby incorporated by reference								or declaration is supplied incorporated by reference.	
The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.  17. CORRESPONDENCE ADDRESS									
or ☐ Correspondence address below  ☐ Correspondence address below  ☐ Correspondence address below  ☐ Correspondence address below  ☐ Address below									
Name	Peter L. Dolan								
DuPont Pharmaceuticals Company – c/o E.I. duPont de Nemours and Co.									
Address	1007 Market Stre								
City	Wilmington		State	Delaware Zip		Zip (	Code	19898	
Country	Country U.S.A. Telephone				(302) 992-4528 Fax		Fax	(302) 992-3999	
Name (Print/Type) Peter L. Dolan					Registration No. (Attorney/Agent) 46,307			46,307	
Signature 4 Con Notes							Date	July 5, 2001	

Burden Hour Statement This form is estimated to take 0.2 hours to complete Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.



Patent and Trademark Office U S DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

07/05/01

7

FEE TRANSMITTAL for FY 2001

Patent fees are subject to annual revision.

2006 00

TOTAL AMOUNT OF PAYMENT (\$)

-						
	Complete if Known					
	Application Number	Unknown				
	Filing Date	July 5, 2001				
	First Named Inventor	Shuang Liu				
	Examiner Name	Unknown				
	Group / Art Unit	Unknown				
	Attorney Docket No.	PH-7176				

	ME	THOD OF	PAYM	ENT (check one)		1			FEE (	CALCULATION (continued)	
The Commissioner is hereby authorized to charge						3. ADDITIONAL FEES					
1. Indicated fees and credit any over payments to.							=	O 11			
						Large Fee	Entity Fee	Small Fee	Entity Fee		Fee
Depo		04 40	20			Code	(\$)	Code	(\$)	Fee Description	Paid
Acco Numi		04-19	20			105	130	205	65	Surcharge - late filing fee or oath	
						127	50	227	25	Surcharge - late provisional filing fee or cover sheet	
Depo Acco				Pharmaceutic	als	139	130	139	130	Non-English specification	
Name ■ Charge An		Comp al Fee Req		· · · · · · · · · · · · · · · · · · ·		147	2,520	147	2,520	For filing a request for ex parte reexamination	
Under 37 Applicant		and 1 17	atus.			112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
See 37 C	FR 1 27					113	1,840*	113	1,840*	Requesting publication of SIR after	
2. Payme	nt Enclos	eu				115	110	215	55	Examiner action  Extension for reply within first month	
☐ Check	☐ Cre	dit card		Money 🔲 Ot Order	her	116	390	216	195	Extension for reply within second month	
		FEE (	CALC	JLATION		117	890	217	445	Extension for reply within third month	
2		ING FEE				118	1,390	218	695	Extension for reply within fourth month	
Large Entity Fee Code		Entity Fee Fe		Fee Description		128	1,890	228	945	Extension for reply within fifth month	
; r ee <b>c</b> oue		Code (\$		ree bescription	Fee Paid	119	310	219	155	Notice of Appeal	
101		201 35		Utility filing fee	710 00	120	310	220	155	Filing a brief in support of an appeal	
106	320 2	206 16	30	Design filing fee		121	270	221	135	Request for oral hearing	
107 108		207 24 208 35		Plant filing fee Reissue filing fee		138	1,510	138	1,510	Petition to institute a public use proceeding	
114		200 35 214 75		Provisional filling fe		140	110	240	55	Petition to revive – unavoidable	
114	130 2	214 /	,	FIOVISIONAL HISING TO		141	1,240	241	620	Petition to revive – unintentional	
	su	BTOTAL (1	I)		(\$) 710 00	142	1,240	242	620	Utility issue fee (or reissue)	
						143	440	243	220	Design issue fee	
2. EXTRA CLAII	M FEES			F.4 F	£	144	600	244	300	Plant issue fee	
				Extra Fee Claims belo	from Fee w Paid	122	130	122	130	Petitions to the Commissioner	
otal Claims	92	-20**	= [	72 X 18		123	130	123	50	Petitions related to provisional applications	
	2	-3**	=	0 X	= 0	126	240	126	240	Submission of Information Disclosure Stmt	
Multiple Dependent  Large Entity		Entity	_	x [	= 0	581	40	581	40	Recording each patent assignment per property (times number of properties)	
Fee Code 103	Fee (\$) 18	Fee Code 203	<b>Fee</b> ( <b>\$</b> )	Fee Description		146	710	246	355	Filing a submission after final rejection (37 CFR § 1 129(a))	
102	80	202	40	•	ims in excess of 3	149	710	249	355	For each additional invention to be examined (37 CFR § 1 129(b))	
104	270 80	204	135 40	** Reissue inder	ent claim, if not paid endent claims over	179	710	279	9 355		
				original patent ** Reissue claim	s in excess of 20 and	(RCE) 169	900	169	9 900	Request for expedited examination	
110	18	210 SUB	9 TOTAI	over original pat		155	300	10.	300	of a design application	
						Other fee (specify)					
						*Red	uced by	Basic F	iling Fee	Paid SUBTOTAL (3) (\$) 0 00	
**or number previo	usly paid, i	f greater, Fo	r Reis	sues, see above							
CUDAUT											

SUBMITTED BY Complete (if applicable)								
Name (Print/Type)	Peter L Dolan Registration No Attorney/Agent)	46,307	Telephone	302-992-4528				
Signature	telanh		Date	July 5, 2001				

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.